公开(公告)号：EP1596811A2

公开(公告)日：2005-11-23

申请号：EP04709875.1

申请日：2004-02-10

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： BEAMAN, Kenneth

IPC: A61K6/00

CPC classification number: C07K16/40 ,  A61K2039/505

Abstract: The present invention is directed to compositions and methods to modulate inflammatory and immune responses in a subject, which includes immune activation and inhibiting inflammatory responses, by modulating the regeneration and tolerance factor (RTF).

公开(公告)号：EP4017981A1

公开(公告)日：2022-06-29

申请号：EP20789084.9

申请日：2020-10-08

Applicant: Johann Wolfgang Goethe-Universität Frankfurt am Main ,  Rosalind Franklin University of Medicine and Science

Inventor： HARTH, Simon ,  OREB, Mislav ,  CHOE, Jun-Yong

IPC: C12N15/52 ,  C12P7/00 ,  C12N9/04

公开(公告)号：EP3259356A1

公开(公告)日：2017-12-27

申请号：EP16714069.8

申请日：2016-02-17

Applicant: Rosalind Franklin University of Medicine and Science ,  Hastings, Michelle L.

Inventor： HASTINGS, Michelle, L.

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/32 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/351 ,  C12N2310/3521 ,  C12N2310/3525 ,  C12N2310/3533 ,  C12N2320/30 ,  C12N2320/33

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

公开(公告)号：EP2552462B1

公开(公告)日：2015-12-16

申请号：EP11763563.1

申请日：2011-04-04

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： RISER, Bruce

IPC: A61K35/12 ,  A61K38/10 ,  C07K7/08 ,  A61P9/10 ,  A61P35/00 ,  A61P19/08 ,  A61P43/00 ,  A61P9/00 ,  A61N1/30

CPC classification number: A61K38/10 ,  A61K38/08 ,  C07K14/4743 ,  C07K14/475

公开(公告)号：EP2552462A2

公开(公告)日：2013-02-06

申请号：EP11763563.1

申请日：2011-04-04

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： RISER, Bruce

IPC: A61K35/12 ,  A61K38/10 ,  C07K7/08 ,  A61P9/10 ,  A61P35/00 ,  A61P19/08 ,  A61P43/00 ,  A61P9/00 ,  A61N1/30

CPC classification number: A61K38/10 ,  A61K38/08 ,  C07K14/4743 ,  C07K14/475

Abstract: The present invention provides a CCN3 peptide for treating a subject in need thereof having an amino acid sequence identified as CCNp37, CCNp38 (human), CCNp38 (mouse), a cysteine-substituted CCNp37, cysteine-substituted CCNp38 (human) or a cysteine-substituted CCNp38 (mouse).

公开(公告)号：EP1841316B1

公开(公告)日：2011-04-27

申请号：EP06717966.3

申请日：2006-01-10

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： RISER, Bruce, L. ,  PERBAL, Bernard

IPC: A61K38/17 ,  A61P13/12

CPC classification number: C07K14/4702 ,  A61K48/00

Abstract: The present invention discloses a role of CCN3 in diseases associated with the overexpression of CCN2, which include but are not limited to kidney disease, fibrosis, and cancer. The full length CCN3 protein or fragments thereof or isoforms (or combinations) of CCN3 are involved in these diseases. The isolated and purified CCN3 protein or its fragments or isoforms (or combinations) of CCN3 can be potentially used in the treatment or prevention of these diseases by regulating the expression and/or activity of the CCN2 protein. The level of CCN3 in tissue or body fluids can also be used to predict, diagnose and/or follow the progression of diseases as well as to determine the effectiveness of therapeutic intervention.

公开(公告)号：EP2126141A2

公开(公告)日：2009-12-02

申请号：EP08726769.6

申请日：2008-03-13

Applicant: UNIVERSITY HOSPITALS OF CLEVELAND ,  Rosalind Franklin University of Medicine and Science ,  Ribonomics, Inc.

Inventor： GORODESKI, George ,  POTASHKIN, Judy ,  CHEATHAM, Bentley

IPC: C12Q1/70 ,  C12Q1/68 ,  C12N15/00 ,  C07H21/04

CPC classification number: C12N15/1138 ,  C12N2310/14 ,  C12N2320/11 ,  C12N2330/10 ,  C12Q1/6809 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/178 ,  C12Q2522/10

Abstract: A relationship between cancer and ribonucleic acid (RNA) regulation is described by determining intracellular levels of niRN A regulators. Generally, mRNA levels are decreased in cancer cells that may be a reflection of either reduced mRNA expression and/or increased mRNA degradation. miRNAs are identified that hybridize to an mRNA that are suspected to mediate intracellular mRNA steady state levels. Alternatively, ribonucleic acid binding protein (RBP) levels may also mediate intracellular mRNA steady state levels. In particular, this invention demonstrates an effective clinical management strategy for uterine cell cancers may be implemented by taking advantage of an exemplary relationship between P2X7 mRNA and miRNAs including, but not limited to, miR-186 and/or miR-150.

公开(公告)号：EP1841316A2

公开(公告)日：2007-10-10

申请号：EP06717966.3

申请日：2006-01-10

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： RISER, Bruce, L. ,  PERBAL, Bernard

IPC: A01N37/18

CPC classification number: C07K14/4702 ,  A61K48/00

Abstract: The present invention discloses a role of CCN3 in diseases associated with the overexpression of CCN2, which include but are not limited to kidney disease, fibrosis, and cancer. The full length CCN3 protein or fragments thereof or isoforms (or combinations) of CCN3 are involved in these diseases. The isolated and purified CCN3 protein or its fragments or isoforms (or combinations) of CCN3 can be potentially used in the treatment or prevention of these diseases by regulating the expression and/or activity of the CCN2 protein. The level of CCN3 in tissue or body fluids can also be used to predict, diagnose and/or follow the progression of diseases as well as to determine the effectiveness of therapeutic intervention.

公开(公告)号：EP1596811A4

公开(公告)日：2007-10-03

申请号：EP04709875

申请日：2004-02-10

Applicant: ROSALIND FRANKLIN UNIVERSITY O

Inventor： BEAMAN KENNETH

IPC: A61K20060101 ,  A61K6/00 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/17 ,  A61K39/395 ,  A61K48/00 ,  A61P29/00 ,  A61P35/00 ,  C07K16/40 ,  C12N15/12 ,  C07K14/705

CPC classification number: C07K16/40 ,  A61K2039/505

公开(公告)号：WO2021069602A1

公开(公告)日：2021-04-15

申请号：PCT/EP2020/078295

申请日：2020-10-08

Applicant: JOHANN WOLFGANG GOETHE-UNIVERSITÄT FRANKFURT AM MAIN ,  ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE

Inventor： HARTH, Simon ,  OREB, Mislav ,  CHOE, Jun-Yong

IPC: C12N15/52 ,  C12P7/00 ,  C12N9/04

Abstract: The present invention relates to polypeptides which are galacturonate (GalA) reductase variants comprising at least one amino acid substitution at a position corresponding to K261 and/or R267. The present invention further relates to nucleic acid molecules encoding the polypeptides and to host cells containing said nucleic acid molecules. The present invention further relates to a method for the production of L-galactonate (GalOA) and/or other bio-based compounds, comprising the expression of said nucleic acid molecules, preferably in said host cells. The present invention also relates to the use of the polypeptides, nucleic acids molecule or host cells for the production of L-galactonate (GalOA) and/or other bio-based compounds, and/or for the recombinant fermentation of biomaterial containing D-galacturonate (GalA).